Author(s):
Susanta Paul, Subhabrota Majumdar, Mainak Chakraborty, Soumyadip Ghosh
Email(s):
susanta.paul@nshm.com
DOI:
10.52711/0974-360X.2025.00080 
Address:
Susanta Paul1*, Subhabrota Majumdar2, Mainak Chakraborty3, Soumyadip Ghosh2
1Department of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata, West Bengal-700041, India.
2Calcutta Institute of Pharmaceutical Technology and Allied Health Sciences, Uluberia, Howrah-711316, India.
3Department of Pharmaceutical Technology, Adamas University, Kolkata, West Bengal-700126, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 2,
Year - 2025
ABSTRACT:
Keratitis left untreated can lead to blindness. Various factors contribute to ocular keratitis, primarily viral infections such as VZV and HSV. Ganciclovir is effective in treating viral keratitis by inhibiting viral DNA polymerase replication, thereby suppressing viral reproduction and delaying the progression of the disease, which ultimately reduces the risk of corneal scarring and perforation. However, the efficacy of ganciclovir in treating ocular keratitis is limited by challenges related to medication delivery and absorption, particularly with conventional eye drops and ointments that quickly evaporate upon contact with the cornea, necessitating frequent administration that may impact patient compliance. To overcome these limitations, researchers have explored nanoparticle-based drug delivery systems. Nanoparticles, particularly those made from biocompatible and biodegradable materials like ethyl cellulose, offer advantages such as controlled drug release, enhanced bioavailability, and improved ocular permeability. Ethyl cellulose nanoparticles can effectively transport drugs to ocular tissues, protect them from degradation, and improve drug absorption, thereby reducing the frequency of dosing and minimizing side effects. In this study, ganciclovir was incorporated into ethyl cellulose nanoparticles using the emulsion-solvent evaporation method. The formulation parameters, including ethyl cellulose and polyvinyl alcohol concentrations, were optimized using a 32 full factorial design. The optimized formulation (B6) demonstrated the lowest errors and had particle size, zeta potential, and encapsulation efficiency values of 178.1nm, -21.53mV, and 53.51%, respectively. Furthermore, the optimized batch exhibited sustained drug release, with 87.14% release observed at 12 hours. Overall, the study highlights the potential of ethyl cellulose nanoparticles as a promising drug delivery system for improving the treatment outcomes of ocular keratitis, with the optimized formulation showing favorable characteristics for effective and sustained drug delivery.
Cite this article:
Susanta Paul, Subhabrota Majumdar, Mainak Chakraborty, Soumyadip Ghosh. Development, Statistical Optimization and Characterization of Ganciclovir Laden Ethyl Cellulose Nanoparticles: A 32 Factorial Design Approach. Research Journal of Pharmacy and Technology.2025;18(2):537-4. doi: 10.52711/0974-360X.2025.00080
Cite(Electronic):
Susanta Paul, Subhabrota Majumdar, Mainak Chakraborty, Soumyadip Ghosh. Development, Statistical Optimization and Characterization of Ganciclovir Laden Ethyl Cellulose Nanoparticles: A 32 Factorial Design Approach. Research Journal of Pharmacy and Technology.2025;18(2):537-4. doi: 10.52711/0974-360X.2025.00080 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-2-12
REFERENCES:
1. Polcicova K, Biswas PS, Banerjee K, Wisner TW, Rouse BT, Johnson DC. Herpes keratitis in the absence of anterograde transport of virus from sensory ganglia to the cornea. ProcNatlAcadSci U S A., 2005; 102(32): 11462-11467. https://doi.org/10.1073/pnas.0503230102
2. Colin J. Ganciclovir ophthalmic gel, 0.15%: A valuable tool for treating ocular herpes. ClinOphthalmol. 2007; 1(4): 441-453.
3. Tsung TH, Tsai YC, Lee HP, Chen YH, Lu DW. Biodegradable polymer-based drug-delivery systems for ocular diseases. Int J Mol Sci., 2023; 24(16): 12976. https://doi.org/10.3390/ ijms241612976
4. Bodas SD, Ige PS. Central composite rotatable design for optimization of budesonide-loaded cross-linked chitosan–dextran sulfatenanodispersion: Characterization, in vitro diffusion and aerodynamic study. Drug DevInd Pharm. 2019; 45(7): 1193-1204. https://doi.org/10.1080/03639045.2019.1606823
5. Kansara V, Hao Y, Mitra AK. Dipeptide monoester ganciclovirprodrugs for transscleral drug delivery: Targeting the oligopeptide transporter on rabbit retina. J OculPharmacolTher. 2007; 23(4): 321-334. https://doi.org/10.1089/jop.2006.0150
6. Rao NS, Leena B. Process Optimization and Evaluation of Immediate Release Tablet containing Benzimidazoles. Asian J Pharm Anal. 2023; 13(3): 180-2.
7. Frijlink HW. De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert opinion on drug delivery. 2004; 1(1): 67-86. doi.org/10.1517/17425247.1.1.67.
8. Daharwal SJ, Thakur VD, Shrivastava S, Sahu BP. Designing and Optimization of Modified Dissolution Apparatus for Evaluation of Medicated Chewing Gum of AmbroxolHCl. Asian J Pharm Res. 2013; 3(3): 141-143.
9. Sapowadia A, Ghanbariamin D, Zhou L, Zhou Q, Schmidt T, Tamayol A, Chen Y. Biomaterial drug delivery systems for prominent ocular diseases. Pharmaceutics. 2023; 15(7): 1959. https://doi.org/10.3390/pharmaceutics15071959
10. Irimia T, Ghica MV, Popa L, Anuţa V, Arsene AL, Dinu-Pîrvu CE. Strategies for improving ocular drug bioavailability and corneal wound healing with chitosan-based delivery systems. Polymers. 2018; 10(11): 1221. https://doi.org/10.3390/ polym10111221
11. Patil MO, Mali YS, Patil PA, Karnavat DR. Development of Immunotherapeutic Nanoparticles for treatment of Tuberculosis. Asian J Pharm Res., 2020; 10(3): 226-232.
12. Bhupendra G. Prajapati, HimanshuPaliwal, Mayuree Patel. Fabrication and Evaluation of Polymeric Nanoparticles of Acitretin for Solubility Enhancement. Research Journal of Pharmacy and Technology. 2023; 16(6): 2655-0. https://doi.org/ 10.52711/0974-360X.2023.00436
13. Wani M, Jagdale S, Khanna P, Gholap R, Baheti A. Formulation and Evaluation of Ophthalmic In-Situ Gel using Moxifloxacin Coated Silver Nanoparticles. Research J Pharm Tech. 2020; 13(8): 3623-3630. https://doi.org/10.5958/0974-360X.2020.00641.1
14. VazirAshfaq Ahmed, HG Shiv Kumar, KLK Paranjothy, Mohd. Khaleel. In-Situ Gel Forming Ophthalmic Drug Delivery System. Research J. Pharm. and Tech. 2009; 2(1): 123-127.
15. Panja A, Mishra AK, Dash M, Pandey NK, Singh SK, Kumar B. Solid Lipid Nanoparticles: A Promising Novel Carrier. Res J Pharm Tech., 2022; 15(12): 5879-5885. https://doi.org/10.52711/ 0974-360X.2022.00992Han H, Li S, Xu M, Zhong Y, Fan W, Xu J, Yao K. Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives. Adv Drug Deliv Rev. 2023; 196: 114770. https://doi.org/10.1016/ j.addr.2023.114770
16. Kumar V, Kumar P, Sharma S. Application of Box-Behnken Experimental Design in Process Parameter Optimization for Production of BerberineHCl loaded Chitosan Coated Sodium Alginate Nanoparticles. Res J Pharm Tech., 2023; 16(3): 1139-1145. https://doi.org/10.52711/0974-360X.2023.00190
17. Reddy SH, Umashankar MS, Damodharan N. Formulation, Characterization and Applications on Solid Lipid Nanoparticles – A Review. Res J Pharm Tech., 2018; 11(12): 5691-5700. https://doi.org/10.5958/0974-360X.2018.01031.4
18. Kumar PR, Lakshmi VA. An Overview on Nanobased Drug Delivery System. Res J Pharm Tech. 2020;13(10):4996-5003. https://doi.org/10.5958/0974-360X.2020.00875.6
19. Umamaheswari R, Kothai S. Effectiveness of Copper nanoparticles loaded microsponges on Drug release study, Cytotoxicity and Wound healing activity. Res J Pharm Tech. 2020; 13(9): 4357-4360. https://doi.org/10.5958/0974-360X.2020.00770.2
20. Jaiswal P, Mishra A, Kesharwani D, Das Paul S. Overview on Ocular Drug Delivery through Colloidal Nano-Suspension. Res J Pharm Tech., 2023; 16(3): 1533-1539. https://doi.org/10.52711/ 0974-360X.2023.00251
21. Nayakal P, Patil A, Kore PS, Mohite SK. Advanced Drug Delivery - Inhalation of Nanoparticles to Treat Coronary Failure. Res J Pharm Tech., 2018; 11(12): 5669-5671. https://doi.org/ 10.5958/0974-360X.2018.01026.0